Business Context and Reporting Period
Company: Inotiv, Inc. (NOTV)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2025
Business Overview: Inotiv is a contract research organization (CRO) providing nonclinical and analytical drug discovery services (Discovery and Safety Assessment segment) and selling research-quality animals and diets (Research Models and Services segment). The company operates globally with facilities in the U.S., U.K., Europe, and other regions.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Total Revenue | $513.0 million | $490.7 million | +4.5% |
| Operating Loss | $(30.9) million | $(86.4) million | Improvement of $55.5 million |
| Net Loss (Attributable to Common Shareholders) | $(68.6) million | $(108.4) million | Improvement of $39.8 million |
| Net Cash Used in Operating Activities | $(10.5) million | $(6.8) million | Worsened by $3.7 million |
| Cash and Cash Equivalents (Sept 30, 2025) | $21.7 million | $21.4 million | N/A |
| Total Debt (Net of issuance costs) | $402.1 million | $393.3 million | +2.2% |
| Revolving Credit Facility Outstanding | $3.0 million | $0 | N/A |
Note: All figures in millions unless otherwise noted. The company reported a net loss for both periods.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4.5% year-over-year, driven by a 4.7% increase in the Research Models and Services (RMS) segment (primarily higher Non-Human Primate (NHP) product and service revenue) and a 4.3% increase in the Discovery and Safety Assessment (DSA) segment.
- Operating Performance: The operating loss narrowed significantly from $86.4 million to $30.9 million. This improvement was primarily due to the RMS segment turning from an operating loss of $31.9 million in 2024 to an operating income of $20.6 million in 2025.
- One-Time Items: The 2024 results included a $28.5 million charge related to a Resolution Agreement and Plea Agreement with the DOJ, which did not repeat in 2025. Conversely, 2025 included a $7.55 million legal settlement gain from Freese and Nichols, Inc. (FNI).
- Debt Structure: In September 2024, the company issued $22.0 million in Second Lien Notes and cancelled $8.3 million of Convertible Senior Notes. As of September 30, 2025, the company classified all long-term debt as current due to anticipated covenant non-compliance.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
The company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern. Management's fiscal 2026 operating plan forecasts noncompliance with financial covenants under its Credit Agreement. If results do not improve, the company risks an event of default, which could trigger acceleration of all outstanding debt (Term Loans, Notes, and Second Lien Notes). The company does not believe its existing cash and cash flows would be sufficient to repay all accelerated debt obligations.
Key Risks and Contingencies
- Cybersecurity Incident: In August 2025, a threat actor gained unauthorized access to company systems. The forensic investigation is complete, but full financial and operational impacts are still being evaluated. Three putative class action lawsuits have been filed related to this incident.
- Internal Controls: Management concluded that disclosure controls and internal controls over financial reporting were not effective as of September 30, 2025, due to material weaknesses in IT general controls and the control environment. The auditor issued an adverse opinion on internal controls.
- Legal Proceedings: The company has reached agreements in principle to settle a Securities Class Action (proposed $8.75 million payment) and Derivative Actions. These settlements are subject to court approval. The company has recorded an $11.0 million liability and a corresponding insurance recovery receivable.
- NHP Supply Chain: The business remains dependent on importing Non-Human Primates (NHPs) from outside the U.S., subject to tariffs (10-20% in 2025) and supply volatility. Sales of NHPs have decreased significantly in recent periods.
- Regulatory Compliance: The company is subject to a five-year compliance monitorship following a Plea Agreement regarding violations of the Animal Welfare Act and Clean Water Act at a former facility.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet financial covenants in the upcoming fiscal quarters to avoid an event of default and debt acceleration.
- Debt Refinancing: Assess the progress of debt refinancing efforts, as the Term Loan Facility and other major debt instruments mature in November 2026.
- Cybersecurity Impact: Monitor updates on the August 2025 cybersecurity incident, specifically regarding the outcome of the three pending class action lawsuits and any additional regulatory penalties.
- Internal Control Remediation: Review the timeline and effectiveness of remediation efforts for the material weaknesses in internal controls over financial reporting.
- Settlement Approvals: Confirm court approval of the proposed Securities Class Action and Derivative Action settlements to finalize the $11.0 million liability.
- NHP Revenue Stability: Evaluate the sustainability of NHP revenue growth given ongoing supply chain constraints, tariff costs, and potential shifts in client demand.